2M, trading at $0.14 on the NASDAQ. This SniperIQ fundamentals page covers Gossamer Bio's valuation, profitability (net margin -324.8%), revenue ($48M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
2M
Net Margin-324.8%
Revenue (FY25)$48M

Full research coverage

Frequently Asked Questions

What is Gossamer Bio's market cap?

Gossamer Bio (GOSS) has a market capitalization of approximately

2M, trading at $0.14 on the NASDAQ. Market cap moves with the live share price.

How profitable is Gossamer Bio?

Gossamer Bio runs a net profit margin of -324.8%, a gross margin of 99.6%, and an operating margin of -321.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Gossamer Bio generate?

Gossamer Bio reported revenue of $48M for fiscal year 2025, with net income of -

Does Gossamer Bio pay a dividend?

Gossamer Bio does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Gossamer Bio financially healthy?

Gossamer Bio carries a debt-to-equity ratio of -1.26x and a current ratio of 2.20x, with a market beta of 2.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Gossamer Bio a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Gossamer Bio (GOSS) the key facts are: market cap

2M, revenue $48M, 52-week range 0.114-3.87. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Gossamer Bio's full fundamentals live

Get Gossamer Bio's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.